1) Patients with both classical MP-positive a |
2) Patients with filigree-predominant ADC sho |
3) Patients with malignancy and solid-organ t |
4) Patients with pretreatment ApoC-II levels |
5) Patients with severe visual vertigo improv |
6) ollected primary care records to identify patients with 'high-risk' conditions, incl |
7) They are disrupted in patients with 22q11.2 deletion syndrome, d |
8) is of single nuclei from brain tissues of patients with AD carrying the R47H mutatio |
9) Therefore, subtyping patients with AD is a critical step toward |
10) -Hispanic white individuals including 109 patients with AD, 356 mild cognitive impai |
11) icrometastasis indicated poor survival in patients with ADC with the filigree patter |
12) Intrarenal scRNA-Seq transcriptomes in patients with AKI-defined cell populations |
13) c EEG abnormalities are present in 80-90% patients with AS. |
14) and rituximab (FCR) in untreated younger patients with CLL. |
15) l GCMH-related pathologies in smokers and patients with COPD. |
16) that although approximately two-thirds of patients with COVID-19 had symptoms of kid |
17) s in acutely meeting the medical needs of patients with COVID-19 while continuing es |
18) ctive smokers were underrepresented among patients with COVID-19, claimed that a "sm |
19) atinine was reported for up to 60% of the patients with COVID-19, the overall preval |
20) nd clinical outcomes among critically ill patients with COVID-19. |
21) is was performed of 693 Japanese COVID-19 patients with CVDRF enrolled in the nation |
22) Conclusions: One-third of COVID patients with CVDRF required ICU care duri |
23) A cohort of 57 head-and-neck cancer patients with DECT and MRI pairs were used |
24) The results revealed that patients with HGSOC and the TT genotype at |
25) In summary, patients with HGSOC and the TT genotype at |
26) at the rs6983267 locus (GG, GT, TT) in 98 patients with HGSOC. |
27) associated with CKD but was restricted in patients with HIV viremia, regardless of C |
28) onal consequence of six VUS identified in patients with IRD. |
29) e presentation and clinical management of patients with IgAn in Europe and Japan. |
30) es of these molecules in the NALT/BALT of patients with IgAn. |
31) addition to the serious somatic symptoms, patients with MD also experience problems |
32) itive functioning and/or mental health in patients with MD and their relatives. |
33) itive impairments and mental disorders in patients with MD. |
|